AMS BioteQ Co., Ltd. (hereinafter "AMS BioteQ") was founded in 2018 with headquarters in Kaohsiung and an R&D laboratory in Tainan Science Park. Our new facility in Qiaotou Science Park, scheduled for completion in 2028, will serve as the company's next-stage research and production base.
Founded with a mission to solve microbial resistance, the company has cultivated deep expertise in natural product extraction, polymer materials engineering, chemical synthesis, and biocompatibility design — ultimately establishing two core technology platforms: PoroVance™ Precision Pore Engineering and Small-Molecule Drug Discovery. Since 2023, these platform capabilities have been extended to four application areas: medical devices, smart agriculture, skincare, and new drug development. Between 2024 and 2026, the company successively obtained medical device certifications from Taiwan TFDA, U.S. FDA, and Japan PMDA, along with multiple invention patents in Taiwan, Japan, and other key markets.
AMS BioteQ is now listed on Taiwan's Emerging Stock Market (Stock Code: 6864), advancing steadily into the international biotech arena.
"The invaluable research comes from innovation, and all our endeavor lies in creating the most profitable compounds"
Two platforms — PoroVance™ Precision Pore Engineering and Small-Molecule Drug Discovery — form the technological dual track of AMS BioteQ. The former extends into three commercial product lines: SIPSIP® advanced wound dressings, SeepPlug™ agricultural substrates, and Lumière d'Art skincare. The latter carries new drug development projects including FORMOSA-1117, YUAN-03, AMS-2140, and the TenTacle™ ADC linker. Four parallel axes, mutually reinforcing, build AMS BioteQ's distinctive platform-type competitive position in the international market.
Starting from Kaohsiung, AMS BioteQ has accumulated R&D strength and expanded into global markets. Our medical devices have passed regulatory review by Taiwan TFDA, U.S. FDA, and Japan PMDA. Our agricultural technology is in active partnerships across Japan, Vietnam, India, and Australia. Our small-molecule drug pipeline has been validated through collaborations with Chulalongkorn University, Mahidol University Siriraj Hospital, Taiwan's National Health Research Institutes, National Taiwan University Hospital, National Cheng Kung University, Kaohsiung Medical University, and Chi Mei Medical Center. From product commercialization to licensing partnerships, AMS BioteQ advances steadily toward the international biotech market.
AMS BioteQ deploys its PDCA-driven intellectual property strategy across multiple invention patents covering dressing manufacturing methods, antibacterial and antiviral compounds, ADC linker conjugates, and precision pore engineering technology — with patent coverage in Taiwan, the United States, Japan, and other key markets. Recent milestones include the granted invention patent for human dressing manufacturing methods in Japan and the granted invention patent for the TenTacle™ linker conjugate compound in Taiwan, laying critical foundations for the SIPSIP® dressing line and future ADC development.